 Panama PetrochemLubricants | Factory operations licence received for Ambernath plant2 Jul 2026Regulatory Product Approval | +2.7% +0.4% +9.9% | ₹486 | 2,940 Cr | 12.6vs 17.3 | 17.3% | +6.4% |
 Kernex Microsys(i)Transport Related Services | Kernex commissions Kavach 4.0 on 207 km North Central Railway section2 Jul 2026Regulatory Product Approval×2 | +3.4% -2.6% +0.2% | ₹1,937 | 3,255 Cr | 37.4 | 43.9% | +440.3% |
 Faze ThreeOther Textile Products | Faze Three gets approval under Government PLI Scheme for textiles segment1 Jul 2026Regulatory Product Approval | +2.1% -1.7% -10.2% | ₹504 | 1,225 Cr | 23.5vs 15.3 | 8.3% | +33.9% |
 Bharti AirtelTelecom - Cellular & Fixed line services | Bharti Airtel subsidiary Airtel Money starts NBFC operations1 Jul 2026Regulatory Product Approval | +2.1% +1.8% +5.4% | ₹1,946 | 11.86 L Cr | 40.6vs 23.1 | 11.9% | +6.2% |
 Taj GVK Hotels & ResortsHotels & Resorts | Taj GVK receives Occupancy Certificate for Taj Yelahanka Bengaluru1 Jul 2026Regulatory Product Approval | +0.6% +10.1% +7.7% | ₹350 | 2,192 Cr | 5.2vs 22.9 | 26.8% | +47.9% |
 Indoco RemediesPharmaceuticals | Indoco Remedies Goa Plant gets EU GMP certification from Malta authority26 Jun 2026Regulatory Product Approval×6 | +3.9% +8.2% -3.0% | ₹226 | 2,086 Cr | — | -6.9% | -1.9% |
 Jubilant PharmovaPharmaceuticals | USFDA tentative approval for Pantoprazole oral suspension26 Jun 2026Regulatory Product Approval | +1.2% +0.9% +1.6% | ₹877 | 13,857 Cr | 39.5vs 28.5 | 4.7% | +16.5% |
 Jindal SawIron & Steel Products | Jindal Saw gets API license reinstated for seamless pipes25 Jun 2026Regulatory Product Approval×2 | +0.8% +1.2% -3.1% | ₹293 | 18,731 Cr | 23.1vs 16.9 | 6.8% | +9.4% |
 Concord BiotechPharmaceuticals | Concord Biotech clears Kenya and Uganda regulator inspections at Unit-II25 Jun 2026Regulatory Product Approval×4 | -1.6% -1.5% -1.9% | ₹1,560 | 16,320 Cr | 58.5vs 28.5 | 16.5% | +32.0% |
 Texel IndustriesPlastic Products - Industrial | Texel Industries gets AASHTO certification for Geotextiles24 Jun 2026Regulatory Product Approval | +28.0% +23.2% +17.4% | ₹69 | 92 Cr | 9.9vs 16.7 | 4.3% | -37.9% |
 Oberoi RealtyResidential Commercial Projects | Oberoi Realty clarifies on RERA registration for Gurugram project24 Jun 2026Regulatory Product Approval | +0.5% +8.7% +4.3% | ₹1,886 | 68,575 Cr | 25.9vs 22.3 | 15.5% | -36.8% |
 Affle 3IIT Enabled Services | Affle 3i gets Indian patent for click-to-install fraud detection24 Jun 2026Regulatory Product Approval×2 | -1.4% -0.9% -0.2% | ₹1,720 | 24,180 Cr | 50.5vs 19.6 | 15.2% | +12.0% |
 Hindustan CopperCopper | Forest Clearance granted for Chandmari copper mine in Rajasthan24 Jun 2026Regulatory Product Approval | -1.9% -0.8% -3.2% | ₹573 | 55,420 Cr | 46.1 | 34.5% | +61.0% |
 Ola Electric Mobility2/3 Wheelers | Ola Electric gets BIS certification for indigenous 46100 LFP cell23 Jun 2026Regulatory Product Approval×2 | +0.7% +4.4% -13.1% | ₹37.75 | 16,652 Cr | — | -37.0% | -61.6% |
 PuravankaraResidential Commercial Projects | Puravankara gets RERA registration for Miami By Purva project in Mumbai19 Jun 2026Regulatory Product Approval×3 | -3.5% -4.1% -2.5% | ₹218 | 5,176 Cr | 14.9vs 22.3 | 3.7% | +133.1% |
 Gravita IndiaIndustrial Minerals | Gravita's Mundra plant gets LME brand accreditation for lead17 Jun 2026Regulatory Product Approval | +3.8% -1.8% +8.5% | ₹1,824 | 13,463 Cr | 35.0vs 18.6 | 17.2% | +13.3% |
 Hybrid Financial ServiceStockbroking & Allied | SEBI grants stock broker registration to Hybrid Financial Services17 Jun 2026Regulatory Product Approval | +36.3% +4.0% -5.0% | ₹17.25 | 51 Cr | 13.9vs 15.8 | 3.5% | +32.5% |
 Godavari Biorefineries LDiversified FMCG | Japanese patent granted for cancer treatment compound16 Jun 2026Regulatory Product Approval×2 | +4.0% -0.9% -8.6% | ₹244 | 1,248 Cr | 10.2vs 16.4 | 0.4% | +31.0% |
 Neetu YoshiCastings & Forgings | Updates- Capacity Cum Capability Approval from Rail Coach factory, Kapurthala10 Jun 2026Regulatory Product Approval×2 | +6.5% +11.5% +5.1% | ₹169 | 656 Cr | 29.3vs 28.9 | 21.8% | — |
 NibeAerospace & Defense | NIBE Limited has informed the Exchange about Nibe Defence and Aerospace Limited, subsidiary of Nibe Limited ( the Company ) has been granted license for manufacturing and proof testing of Firearms by Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce & Industry, Government of India6 Jun 2026Regulatory Product Approval | -3.5% +2.3% -6.7% | ₹1,483 | 2,216 Cr | — | 0.9% | +253.7% |
 AvenuesaiFinancial Technology (Fintech) | Receipt of In-Principle Approval by Avenues World FZ LLC, Step Down Subsidiary Company from Central Bank of the UAE for a Retail Payment Services - Category III License4 Jun 2026Regulatory Product Approval | -1.4% +2.7% +21.2% | ₹15.25 | 5,326 Cr | 14.8vs 90.9 | 6.2% | +26.7% |
 Jeena Sikho LifecareWellness | Jeena Sikho Lifecare Limited Has Informed the Exchange About Receipt of NABH Accreditation for Bhopal Hospital.3 Jun 2026Regulatory Product Approval | -10.1% -12.8% -19.7% | ₹507 | 6,300 Cr | 26.6 | 52.2% | +13.5% |
 Shelter PharmaPharmaceuticals | Initimation under Regulation 30 of SEBI (LODR) Regulations 2015- Receipt of Good Manufacturing Practices Certificate3 Jun 2026Regulatory Product Approval×2 | -1.5% -8.7% -11.2% | ₹32 | 53 Cr | 2.5vs 28.5 | 15.8% | +92.4% |
 Bliss GVS PharmaPharmaceuticals | Bliss GVS Pharma Limited has informed the Exchange about Intimation of WHO-GMP Compliance of Manufacturing Facility located at Survey No. 43 & 44, Vevoor Village, Palghar (East).2 Jun 2026Regulatory Product Approval | +4.0% +0.2% +15.6% | ₹576 | 6,095 Cr | 51.7vs 28.5 | 15.1% | +5.2% |
 WockhardtPharmaceuticals | Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release - "Wockhardt Receives U.S. FDA Approval for ZAYNICH (cefepime and zidebactam), a Novel Intravenous Antibiotic ....30 May 2026Regulatory Product Approval×5 | -2.6% -9.0% -2.8% | ₹1,888 | 30,586 Cr | 68.2vs 28.5 | 3.4% | +23.4% |
 Broach Lifecare Hospital LimitHospital | The Company has received permanent Certificate for Registration of Clinical Establishment from Government of Gujarat, Health and Family Welfare Department for 50 bed Capacity at Hospital ....29 May 2026Regulatory Product Approval | — — -10.0% | ₹18.2 | 11 Cr | 5.6vs 44.9 | 2.2% | — |
 Corona RemediesPharmaceuticals | CORONA Remedies Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Receipt of EU-GMP Certificate".28 May 2026Regulatory Product Approval×2 | +0.5% +5.7% +17.1% | ₹2,147 | 13,132 Cr | 72.9vs 28.5 | 28.5% | -2.2% |
 Quadrant Future TekCables - Electricals | Intimation regarding update on approval process w.r.t. KAVACH System (Ver 4.0)26 May 2026Regulatory Product Approval×3 | +2.4% +17.5% +54.9% | ₹405 | 1,621 Cr | — | -19.8% | +64.4% |
 One Mobikwik SystemsFinancial Technology (Fintech) | In-Principle authorisation to operate as a Payment Aggregator - Physical under the Payment and Settlement Systems Act, 2007 received from the Reserve Bank of India26 May 2026Regulatory Product Approval×5 | +4.6% +1.4% +4.6% | ₹196 | 1,546 Cr | 90.9vs 90.9 | -11.2% | +6.8% |
 Eki Energy ServicesConsulting Services | Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Grant of Inter-state electricity Trading Licence (Category ''IV'') by the ....26 May 2026Regulatory Product Approval | +9.0% -1.3% -2.0% | ₹78 | 216 Cr | 12.6vs 8.5 | -3.0% | +12.4% |
 Venus RemediesPharmaceuticals | Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies receives Saudi FDA approval for Plerixafor its first Maketing Authorization for the specialty oncology therapy globally'.22 May 2026Regulatory Product Approval×2 | +10.8% +44.6% +63.9% | ₹1,747 | 2,335 Cr | 16.0vs 28.5 | 19.4% | +34.6% |
 360 One WamStockbroking & Allied | We wish to inform you that 360 ONE Asset Management Limited (AMC), a wholly owned subsidiary of the Company, has received ''No Objection'' letter from SEBI on May 21, 2026, to undertake ....22 May 2026Regulatory Product Approval×3 | +2.6% -3.8% +2.0% | ₹1,199 | 48,691 Cr | 38.6vs 15.8 | — | +0.1% |
 Sakar HealthcarePharmaceuticals | Sakar Healthcare Limited has informed the Exchange about Sakar enters it s 40th agreement signed with Zydus Lifesciences to cater oncology products to GCC and other emerging markets, in parallel to building momentum on strong execution and expanding Business Opportunities21 May 2026Regulatory Product Approval | -6.3% +2.8% +1.1% | ₹913 | 2,031 Cr | 47.8vs 28.5 | 10.7% | +23.5% |
 Shaily Eng PlasticsPlastic Products - Consumer | Submission of Press Release titled "Shaily Engineering Plastics Limited Announces Regulatory Approval & Launch of Customer Combination Product Incorporating its ShailyPen Neo Device Technology"20 May 2026Regulatory Product Approval | +4.3% +19.4% +5.1% | ₹3,323 | 15,269 Cr | 98.5vs 15.6 | 28.3% | -7.7% |
 Aditya Birla Real EstResidential Commercial Projects | Update on Birla Estates Achieves INR 1007 Crores Sales Booking at Birla Taranya, Thane.20 May 2026Regulatory Product Approval | -1.6% -2.2% +3.0% | ₹1,398 | 15,614 Cr | — | -5.6% | -15.6% |
 MRPLRefineries & Marketing | Mangalore Refinery and Petrochemicals Limited has informed the Exchange about Bagging/Receiving of orders/contracts19 May 2026Regulatory Product Approval | +3.4% +1.6% +6.3% | ₹177 | 30,934 Cr | 9.9vs 5.2 | 15.7% | +9.8% |
 Zim LaboratoriesZIMLAB | Please find attached a press release dated 19th May 2026 titled "ZIM Laboratories Limited announces grant of Marketing Authorization (MA) for Dabigatran Etexilate (75 mg, 110 mg &150 mg) ....19 May 2026Regulatory Product Approval×3 | -1.5% +1.0% +22.9% | ₹125 | 669 Cr | 37.6 | 2.4% | +18.7% |
 Aditya Birla CapitalInvestment Company | Aditya Birla Capital Limited informed the Exchange about the receipt of certificate of registration from RBI to carry on the business of factoring.19 May 2026Regulatory Product Approval×2 | -0.7% +0.0% +11.9% | ₹413 | 1.08 L Cr | 26.0vs 24.9 | — | +27.0% |
 Healthy Life AgritecDairy Products | Intimation of receipt of Statutory License for Manufacturing unit in Banglore under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015.19 May 2026Regulatory Product Approval | +3.9% -6.9% +8.5% | ₹6.48 | 32 Cr | 4.4vs 19.0 | 8.2% | +1.6% |
 Accretion NutravedaPharmaceuticals | Accretion Nutraveda Limited has informed the Exchange regarding Press Release dated 15th May, 2026, titled "Company Delivers Robust Performance in H2 FY26 : Revenue up 80.09% YOY and EBITDA ....15 May 2026Regulatory Product Approval | pending | ₹286 | 207 Cr | 63.1vs 28.5 | 15.8% | — |
